Neurogene Inc.(NGNE)

Biotechnology · New York City, NY

$25.79-0.68 (-2.57%)

Delayed quote: Oct 6, 2026, 2:55 PM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T18:57:54.673Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:57:54.673Z.

Quote observation: 2026-10-06T18:55:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 407,541,988
Total debt · period ending 2026-06-30: 8,345,000
Cash · period ending 2026-06-30: 112,485,000
TTM free cash flow · period ending 2026-06-30: -87,111,669

FMP input reference: 8656b7a9da6ad27e4e3bee00a1f051c5b9ad9ad1f17b43070ca9e23e03b297bf

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NGNE EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

NGNE Competitors' EV/FCF Ratio

NGNE

Neurogene Inc.

Current

Market Cap

$407.54M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RZLT

Rezolute, Inc.

vs NGNE

Market Cap

$407.80M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CARL

Carlsmed, Inc.

vs NGNE

Market Cap

$405.87M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVIR

Atea Pharmaceuticals, Inc.

vs NGNE

Market Cap

$403.79M

EV/FCF Ratio

N/A

TTM Avg

5.74x

3Y Avg

5.74x

5Y Avg

5.74x

MYGN

Myriad Genetics, Inc.

vs NGNE

Market Cap

$403.77M

EV/FCF Ratio

N/A

TTM Avg

3927.74x

3Y Avg

907.14x

5Y Avg

462.84x

SRTA

Strata Critical Medical, Inc.

vs NGNE

Market Cap

$411.43M

EV/FCF Ratio

N/A

TTM Avg

196.27x

3Y Avg

196.27x

5Y Avg

196.27x

Shoulder Innovations, Inc.

vs NGNE

Market Cap

$401.91M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MPLT

MapLight Therapeutics, Inc.

vs NGNE

Market Cap

$414.39M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EIKN

Eikon Therapeutics, Inc. Common Stock

vs NGNE

Market Cap

$416.60M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SENS

Senseonics Holdings, Inc.

vs NGNE

Market Cap

$417.10M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Neurogene Inc. (NGNE)	$407.54M	N/A	N/A	N/A	N/A
Rezolute, Inc. (RZLT)vs ›	$407.80M	N/A	N/A	N/A	N/A
Carlsmed, Inc. (CARL)vs ›	$405.87M	N/A	N/A	N/A	N/A
Atea Pharmaceuticals, Inc. (AVIR)vs ›	$403.79M	N/A	5.74x	5.74x	5.74x
Myriad Genetics, Inc. (MYGN)vs ›	$403.77M	N/A	3927.74x	907.14x	462.84x
Strata Critical Medical, Inc. (SRTA)vs ›	$411.43M	N/A	196.27x	196.27x	196.27x
Shoulder Innovations, Inc. (SI)vs ›	$401.91M	N/A	N/A	N/A	N/A
MapLight Therapeutics, Inc. (MPLT)vs ›	$414.39M	N/A	N/A	N/A	N/A
Eikon Therapeutics, Inc. Common Stock (EIKN)vs ›	$416.60M	N/A	N/A	N/A	N/A
Senseonics Holdings, Inc. (SENS)vs ›	$417.10M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

NGNE EV/FCF Ratio Metrics

NGNE Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics